Cite

HARVARD Citation

    Chen, Z. et al. (n.d.). 137PSignificant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer. Annals of oncology. p. . [Online]. 
  
Back to record